Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
69.00
-0.80 (-1.15%)
At close: Mar 26, 2026
Market Cap10.86B -16.3%
Revenue (ttm)1.62B +71.6%
Net Income683.16M +50.7%
EPS4.53 +40.9%
Shares Out157.33M
PE Ratio15.22
Forward PEn/a
Dividend1.51 (2.16%)
Ex-Dividend Daten/a
Volume200,673
Average Volume357,919
Open70.80
Previous Close69.80
Day's Range68.90 - 70.80
52-Week Range55.00 - 154.00
Beta0.79
RSI25.54
Earnings DateApr 14, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a... [Read more]

Sector Healthcare
Founded 2014
Employees 13
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

In 2024, Handa Pharmaceuticals's revenue was 830.67 million, a decrease of -24.92% compared to the previous year's 1.11 billion. Earnings were 472.74 million, a decrease of -34.96%.

Financial Statements